Swiss National Bank Raises Stake in Labcorp Holdings Inc. $LH

Swiss National Bank grew its stake in Labcorp Holdings Inc. (NYSE:LH) by 6.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 243,260 shares of the medical research company’s stock after acquiring an additional 15,240 shares during the quarter. Swiss National Bank’s holdings in Labcorp were worth $64,904,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of LH. Victory Capital Management Inc. grew its holdings in shares of Labcorp by 103.1% in the fourth quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock valued at $1,343,922,000 after purchasing an additional 2,719,475 shares during the period. Boston Partners acquired a new stake in Labcorp during the fourth quarter worth about $480,271,000. Norges Bank purchased a new position in Labcorp during the fourth quarter worth about $248,006,000. Wellington Management Group LLP raised its stake in Labcorp by 15.9% during the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after purchasing an additional 289,029 shares during the period. Finally, Marshall Wace LLP boosted its holdings in Labcorp by 79.1% in the 3rd quarter. Marshall Wace LLP now owns 623,550 shares of the medical research company’s stock valued at $178,996,000 after purchasing an additional 275,454 shares during the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on LH shares. Robert W. Baird increased their price target on shares of Labcorp from $335.00 to $338.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Evercore reiterated an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. Weiss Ratings reissued a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Finally, Bank of America lifted their target price on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Nine analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Labcorp has a consensus rating of “Moderate Buy” and a consensus price target of $314.40.

Insider Activity at Labcorp

In related news, EVP Kathryn W. Kyle sold 762 shares of Labcorp stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $263.89, for a total value of $201,084.18. Following the completion of the transaction, the executive vice president owned 3,813 shares in the company, valued at approximately $1,006,212.57. The trade was a 16.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan T. Vaughn sold 234 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the sale, the executive vice president directly owned 6,746 shares in the company, valued at approximately $1,930,637.74. The trade was a 3.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 6,991 shares of company stock worth $1,796,696. Corporate insiders own 0.84% of the company’s stock.

Labcorp Price Performance

LH stock opened at $279.10 on Wednesday. The business’s fifty day moving average price is $267.17 and its 200 day moving average price is $268.41. Labcorp Holdings Inc. has a 12-month low of $244.52 and a 12-month high of $293.72. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $22.89 billion, a PE ratio of 24.72, a P/E/G ratio of 1.87 and a beta of 0.89.

Labcorp (NYSE:LH) last released its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $0.16. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.Labcorp’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, sell-side analysts anticipate that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is presently 25.51%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.